Eidogen-Sertanty Announces Collaboration with KAI Pharmaceuticals
News Oct 19, 2005
Eidogen-Sertanty, Inc. has announced that they have engaged in a collaborative service project with KAI Pharmaceuticals.
Under the terms of the service arrangement, Eidogen-Sertanty will utilize the Target Informatics Platform (TIP™) and EVE Comparative Visualization software within its DirectDesign™ Discovery Service to perform extensive structural characterization and comparative binding site analysis for PKC regulatory domains.
The collaborative project will allow KAI to further enhance its insights into PKC isozyme selectivity, as well as to advance KAI's strategies for pharmacophore-based design of modulators of PKC activity.
KAI is developing specific and selective modulators of PKCs for a variety of human diseases, with its lead product in clinical development for acute cardiovascular diseases.
“The unique attributes of Eidogen-Sertanty’s EVE Visualization Software provide powerful capabilities for protein comparison and pharmacophore mapping,” said Derek Maclean, Senior Scientist at KAI Pharmaceuticals.
“We view our relationship with Eidogen-Sertanty as a potentially important part of our drug design strategy.”
“We are very pleased to work with KAI on this project. In addition to our software and database business, our DirectDesign Discovery Service offering allows product-focused companies such as KAI to gain significant value from the proteome-wide comparative structural informatics capabilities of our TIP platform,” said Steve Muskal, CEO of Eidogen-Sertanty.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE